March 26th, 2012
ACC.12 Roundup
CardioExchange Editors, Staff
CardioExchange has been dedicated to bringing you the latest from ACC 2012, and even though the meeting has ended, the buzz has just begun! Check out our coverage below ─ and some of the great debates these posts have sparked ─ then tell us what you think!
Previews:
News:
- Novel Antiplatelet Agent Reduces CV Events But Increases Bleeding
- Study Supports PCI Without On-Site Surgical Backup
- CT Angiography to Rule Out CAD in Chest-Pain Patients
- PARTNER: TAVR Results Appear Durable at 2 Years
- Rivaroxaban Found Safe and Effective for Pulmonary Embolism
- Bariatric Surgery Turns Back the Clock on Diabetes
- ASCERT Observational Study Finds Long-Term Advantage for CABG over PCI in High-Risk Cases
- What to Do When Federal Investigators Knock on the Door
- 20 Deaths Linked to New Problem with Riata Leads
- Proof-of-Concept for Bedside Rapid Genotyping Test of CYP2C19
Analysis:
Follow the Fellows:
- Early Morning, Early Start to ACC
- Honoring the Legends
- On the Shoulders of Giants
- Opening with a Bang
- Whither Conferences? Searching for the South by Southwest Passage
- The Pie-ing Game: How Do We Carve up Shrinking Reimbursements?
- Is it Impossible to Break into Clinical Research? Debunking a Common Misperception
- Face to Face with the Living Legends
- Why Being at ACC in Person Matters
- Academics vs. Private Practice
- Meet the New Boss, Same as the Old Boss — The Affordable Care Act and Medical Liability
- An Inspiring Run
- ACC: Not a Straightforward Science Meeting
- Statistical Pitfalls: The Onus is on Us to Look at the Evidence
- Transitioning from Trainee to Attending? The Business Details
- Presentation Day, At Last
- A Great Take-Away Message
- Final Note from ACC: Insights on Board (Re)Certification
An Inspiring Run
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?